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Abstract The purpose of this study is to determine clinical
factors associated with complications of drug-induced
seizures. This prospective observational study was con-
ducted at an American Association of Poison Control
Centers-certified regional poison control center (PCC) over
a 1-year period. All consecutive cases reported to a PCC
involving seizures were forwarded to investigators, who
obtained standardized information including the specific
drug or medication exposure, dose, reason for exposure,
vital signs, laboratory data, treatment, and outcome.
Patients were monitored by daily telephone follow-up until
death or discharge. Subjects were excluded if the seizure
was deemed to be unrelated to exposure. Odds ratios were
used to analyze variables for associations with admission to
the hospital for >72 h, endotracheal intubation, status
epilepticus, anoxic brain injury, or death. One hundred
twenty-one cases met inclusion criteria. Sixty-three (52%)
were male, and the mean age was 30 (SD14)years.
Common exposures included: antidepressants (33%),
stimulants (15%), and anticholinergics (10%). One hundred
and three (85%) of the exposures were intentional, of which
74 were suicide attempts and 16 were drug abuse or misuse.
Forty-nine (40%) patients required endotracheal intubation,
12(10%) had status epilepticus, 50(41%) were hospitalized
for more than 72 h, and one patient died. Median hospital stay
was 3 days. Variables significantly associated with complica-
tions included stimulant exposure (odds ratios, OR=11 [95%
confidence intervals (CI) 1.9–52]), suicide attempt (OR=2.2
[95% CI 1.02–4.7]), initial hypotension (OR=11.2 [95% CI
1.4–89.3]),admissionglucose>130mg/dL(OR=5.4[95%CI
1.6–18.1]), and admission HCO3<20 mEq/L (OR=4.0 [95%
CI 1.4–11.3]). Significant clinical factors associated with
complications of drug-related seizures include stimulant
exposure, suicide attempt, initial hypotension, and admission
acidosis or hyperglycemia.
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Introduction
It is estimated that 2–5% of the population will have at least
one nonfebrile seizure in their lifetime [1]. It is the
responsibility of the treating physician to terminate the
seizure, prevent complications, identify life-threatening
causes, determine disposition, and minimize morbidity
and mortality for this condition [2]. Seizures are a serious
complication associated with medication or drug use, which
can result in hyperthermia, acidosis, anoxic brain injury, an
eightfold risk of aspiration pneumonitis, and nearly 2%
mortality [3, 4]. A prospective study of status epilepticus
revealed that ethanol and drug overdose is responsible for
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DOI 10.1007/s13181-010-0096-418% of cases of status epilepticus with a fatality rate of
over 20% [5]. It is estimated that 6.1% of new onset
seizures are drug-related [6]. Other studies have determined
that up to 9% of cases of status epilepticus presenting to the
Emergency Department may result from drug toxicity, and
drug-induced seizures may result in status epilepticus up to
5% of the time [7, 8]. Additionally, changing prescription
and drug abuse patterns are reflected in the incidence of
substances attributable to seizures [4].
Currently, few studies help inform clinicians as to which
drug-induced seizure patients are at greatest risk for
complications and mortality. Retrospective studies have
suggested that substance type and hyperthermia may be
associated with mortality in this patient population, while
others have maintained that age, anoxia, and duration of
seizure in status epilepticus are predictors of mortality
[4, 9, 10]. No prospective studies have been conducted on
this topic. Ascertaining the probable clinical course and
likelihood for complications related to drug-induced
seizures can guide patient disposition decisions, foster
cost-effective management, and optimize treatment.
The objective of this study was to determine risk factors
associated with morbidity and mortality from drug-induced
seizures. We defined a complicated hospital course as:
admission to the hospital for greater than 72 h (for reasons
other than psychiatric or social placement), the need for
endotracheal intubation, development of status epilepticus,
anoxic brain injury, or death. We sought to determine
clinical factors of drug-induced seizures associated with a
complicated hospital course.
Materials and Methods
Study Setting This prospective observational study was
conducted at a single American Association of Poison
Control Centers-certified regional poison control center
over a 12-month period. The San Francisco Division of the
California Poison Control System (SFCPCS) has served
nearly a quarter of the population of California since 1997.
The SFCPCS provides 24-h hotline service to the residents
within its catchment area. It is consulted on over 70,000
cases annually involving exposure to drugs or potentially
toxic substances. All hospitalized exposure cases are
routinely followed by staff to assist with management and
determine outcome. Staff members included pharmacists
certified as specialists in poison information and medical
toxicologists. The institutional review board at our affiliated
university approved this study.
Selection of Participants The study population included all
patients presenting with toxin or drug-induced seizure. All
consecutive reported cases to the SFCPCS involving a
seizure were included in this investigation. Callers were
asked for specific patient care related clinical information
necessary to correctly diagnose and treat the problem,
according to our usual practice. The case was subsequently
forwarded to investigators who obtained uniform informa-
tion regarding: the drug, medication or toxin involved,
estimated dose, time to treatment, patient demographics
such as age and gender, reason for the exposure, a
description of the seizure activity, who witnessed the
seizure, the patient’s past medical history, initial and
subsequent vital signs, laboratory data, gastrointestinal
decontamination methods, treatment provided, response to
treatment, complications, and final outcome.
Investigators began collecting data within 12 h of the
initial call, using a standardized data extraction form to
ensure consistency of data collection and minimize bias.
Since no gold standard for a tool of this type exists, the
investigators created this form. Prior to initiating the
study, the standardized form was used to extract data
retrospectively from patient charts and then piloted
prospectively on ten subjects. Based on these results, the
form was modified for ease of use and to minimize
interobserver variability. Blinding was not possible, since
the investigators were also the data collectors. Data were
obtained from health-care providers at the treating facility
including physicians, nurses, physician’s assistants, and
laboratory personnel.
Patients were monitored by daily telephone follow-up
with the admitting hospital until death or discharge in
order to obtain information about clinical status, reasons
for continued hospitalization, and complications. Cases
were excluded if follow-up information was not available
(i.e., if the patient discharged from the emergency
department, and/or health-care workers were unable or
unwilling to provide clinical information about the patient).
Cases were also excluded if the seizure was determined not
to be drug- or toxin-related using an adverse drug reaction
(ADR) scoring system [11]. This ADR score is a well-
accepted method of determining causality for adverse
drug events. A retrospective pilot study amongst three
researchers on this project revealed good intraobserver
reliability and is published previously as part of a separate
study [4]. Of note, the causality classification was affected
by the prior presence of an underlying seizure disorder.
Subjects were excluded if the relationship between the
seizure and exposure was determined to be “doubtful” or
“coincidental.” If more than one drug or medication was
involved in the exposure, the substance with a previously
described causal association with seizures was attributed
as the most likely causal agent.
Outcome Measurement The primary outcome assessed was
the development of a complicated hospital course. We
J. Med. Toxicol. (2011) 7:16–23 17defined this composite outcome measure as having one of
the following: admission to the hospital for greater than
72 h (for reasons other than psychiatric or placement), the
need for endotracheal intubation, status epilepticus, anoxic
brain injury, or death. We did not consider admission to
intensive care unit (ICU) by itself as a complication
because previous experience had shown that criteria for
ICU admissions for this patient population vary widely in
our catchment area and often include convenience for
suicide risk observation. As a secondary outcome measure,
we evaluated the incidence of each of these complications
independently (status epilepticus, endotracheal intubation,
anoxic brain injury, and death).
We evaluated the impact of ten predictor variables on
these outcomes. Predictors included gender, reason for expo-
sure, substance type, primary decontamination method,
initial antiepileptic medication given (after benzodiaze-
pines), presence of initial acidosis, hyperthermia, rhabdo-
myolysis, hyperglycemia, or hypotension. For gender,
male was used as the reference group. Hypotension was
defined as an initial systolic blood pressure less than
90 mmHg. Acidosis was defined as initial pH<7.30 or
HCO3<20 mEq/L. Hyperthermia was defined as initial
temperature greater than 38°C. Rhabdomyolysis was
defined as initial CPK>1,000 U/L. Status epilepticus
was defined operationally in accordance with previous
studies as continuous or repeated seizure activity lasting
greater than 10 min without recovery of consciousness
[12]. Electroencephalogram confirmation was not required
for classification. Substances were classified into one of
six categories for purpose of analysis: antidepressant,
antiepileptic, isoniazid, stimulant, anticholinergic, or other.
These categories were selected based on a previously
published dataset by the same authors reporting the
epidemiology of drug-related seizures for this region [4].
Data Analysis We evaluated each predictor variable in a
univariate analysis using odds ratios and 95% confidence
intervals for associations with the main outcome.
Variables which met p values <0.05 were included in a
logistic regression model to assess for independent
associations with the composite outcome measure. For
descriptive statistics, mean and standard deviation values
were reported for normally distributed data, while median
and interquartile ranges were used for nonparametric data.
Univariate analyses were conducted using chi squared
tests and odds ratios. Univariate and multivariate analyses
were conducted using logistic regression. All analyses
were performed using Epi Info (Version 3.4.3, 2007),
Microsoft Excel 2008, and SAS (Version 9.1.3 for
Windows). Based on an estimated complication rate of
50%, a sample size of 124 was determined to be required
to obtain 80% power.
Results
There were 138 patients with seizures reported to the
SFCPCS during the study period. Investigators were notified
of and able to follow up on 132 (96%) of these. Two subjects
were eliminated because of inadequate information. Another
nine subjects were excluded because causality assessment
deemed the seizure to be unrelated to the exposure. Of these
nine excluded cases—five were found to have an underlying
seizure disorder with medication noncompliance, one was
determined to have pseudoseizures, and three had febrile
seizures. This left 121 subjects available for inclusion into
the analysis.
Table 1 details the frequency of specific exposures in
this population. For purposes of analysis, all substances
were categorized in one of six categories: antidepressants
(33.9%), stimulants (14.9%), anticholinergics (9.9%), INH
(6.6%), antiepileptic (11.6%), or other (23.1%).
Demographic features, presenting signs, initial treatment,
and incidence of complications are presented in Table 2.
Thirteen of 14 patients who experienced aspiration pneumo-
nia were also intubated. There was no difference in mean age
between the complication group and noncomplicated group.
Total number of patients who met the definition of having a
complicated hospital course was 72 (60%). Median length of
hospital stay was 3 days (IQR, 2–5) overall; the length of
stay was 2 days (IQR, 1–2) for the noncomplication group
and 4 days (IQR, 3–6.25) for the complications group.
Table 1 Breakdown of exposures by substance N=121
Substance Frequency (Number/%)
Tricyclic antidepressant 2 (1.7%)
Bupropion 18 (14.9%)
Venlafaxine 2 (1.7%)
Citalopram/escitalopram 10 (8.3%)
Quetiapine 4 (3.3%)
Other antidepressants 4 (3.3%)
Cocaine 6 (5.0%)
Amphetamine 5 (4.1%)
MDMA/Ecstasy 3 (2.5%)
Other Stimulant 4 (3.3%)
Isoniazid 8 (6.6%)
Tramadol 2 (1.7%)
NSAID 1 (0.8%)
Dextromethorphan 3 (2.5%)
Theophylline 1 (0.8%)
Antiepileptic 15 (12.4%)
Other 22 (18.2%)
Diphenhydramine 8 (6.6%)
Doxylamine 3 (2.5%)
18 J. Med. Toxicol. (2011) 7:16–23Eighty subjects were admitted to the intensive care unit. The
median length of ICU stay was 2 days (IQR, 0–3); 0 days
(range, 0–3) for the noncomplication group and 3 days
(range, 2–14) for the complications group. For subjects who
were intubated, the median length of intubation was 2 days
(IQR, 1–4; range, 1–12). Eight subjects were known to have
an underlying seizure history. Information on time delay to
presentation was available for only 23 (19%) subjects. For all
23 of these subjects, there was an immediate EMS response
with arrival of less than 15 min.
Fifty-one subjects had coingestants. The number of
exposed substances per subject ranged from 1 to 7, with a
median of 1 for each group. Of the coingestants: 18 were
selective serotonin reuptake inhibitor antidepressants, 5
narcotics, 4 ethanol, 3 benzodiazepines, 3 carisoprodol, and
3 ibuprofen. The remainder of the coingestants was found
to have only been ingested at therapeutic levels.
For initial treatment of seizures, 96 subjects were given a
benzodiazepine (82 received lorazepam, 8 received diaze-
Table 2 Characteristics of study subjects (N=121)
Variable Number (%)
Age (mean(SD)) 30 (14)
Gender (male) 63 (52%)
Number of substances (median(IQR)) 1 (1–3)
Reason
Abuse 16 (13.2%)
Suicide 74 (61.2%)
Unintentional 18 (14.8%)
Presentation
Acidosis 40 (33.1%)
Hypotension 16 (13.2%)
Hyperthermia 22 (18.2%)
Rhabdomyolysis 21 (17.4%)
Hypoglycemia 3 (2.5%)
Hyperglycemia 23 (19%)
Treatment
Charcoal 45 (37.2%)
Whole bowel irrigation 6 (5%)
Gastric lavage 11 (9.1%)
Phenytoin 12 (9.9%)
Phenobarbital 11 (9.1%)
Benzodiazepine 96 (79.3%)
Complication
Anoxic brain injury 5 (4.1%)
Aspiration pneumonia 14 (11.6%)
Coma 43 (35.5%)
Death 1 (0.8%)
Endotracheal intubation 49 (40.5%)
Status epilepticus 12 (9.9%)
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J. Med. Toxicol. (2011) 7:16–23 19pam, 6 received midazolam), 3 received phenobarbital, 1
received pyridoxine, and 19 received no treatment. Twenty-
nine of the subjects were given a medication strictly for
seizure prophylaxis. Fifty-one subjects were given more than
one drug for seizure termination. Seven subjects received
paralysis in an attempt to control convulsions. Seizure
termination was directly attributable to drug therapy in 64
subjects—43 from lorazepam, 7 from midazolam, 7 from
diazepam, 5 from phenobarbital, and 2 from propofol.
Eight of the 12 subjects with status epilepticus were
intubated, five developed hyperthermia, two developed
aspiration pneumonia, one suffered an anoxic brain injury,
and one died. Of the patients who experienced status
epilepticus, six ingested a stimulant, one isoniazid, three
tiagabine, one nortriptylline, and one bupropion. In this
subgroup, seven were suicidal and three ingested the
substance for purposes of abuse. Ten of the patients with
status epilepticus were refractory to benzodiazepines.
All subjects with anoxic brain injury or death were
intubated. Table 3 presents a description of these cases. Of
Fig. 1 Breakdown of study patients with complications. LOS length
of stay, ETT endotracheally intubated, SE status epilepticus, ABI
anoxic brain injury
Table 4 Main results
Predictor Complicated hospital
course* (N=72)
Endotracheal
intubation (N=49)
Anoxic brain
injury/death (N=6)
Status epilepticus
(N=12)
Gender 1.0 (0.5–2.1) 1.1 (0.5–2.4) 2.1 (0.4–12.2) 0.8 (0.2–2.5)
Reason
Suicide 1.8 (0.9–3.9) 1.8 (0.9–4.0) 1.3 (0.2–7.4) 0.9 (0.3–2.9)
Abuse 1.6 (0.5–4.8) 2.4 (0.8–7.1) 1.4 (0.2–12.9) 2.5 (0.6–10.3)
Unintentional 0.3 (0.1–0.8)
a 0.1 (0.01–0.5) 0 (NA) 1.2 (0.2–5.8)
Substance
Antidepressant 0.6 (0.3–1.4) 0.5 (0.2–1.1) 0.4 (0.04–3.5) 0.4 (0.1–1.7)
Antiepileptic 1.2 (0.4–3.9) 0.8 (0.2–2.4) 1.5 (0.2–14.1) 3.0 (0.7–12.6)
Isoniazid 0.6 (0.2–2.7) 0.8 (0.2–3.7) 0 (NA) 1.3 (0.2–11.8)
Stimulant 3.9 (1.1–14.5)
a 4.2 (1.4–12.7) 1.2 (0.1–10.9) 8.1 (2.2–29.1)
Anticholinergic 0.6 (0.2–2.1) 0.7 (0.2–2.4) 1.8 (0.2–17.2) 0 (NA)
Other 1.0 (0.4–2.5) 1.3 (0.6–3.1) 1.6 (0.3–9.5) 0 (NA)
Decontamination
Charcoal 1.3 (0.6–2.7) 1.5 (0.7–3.2) 0.8 (0.1–4.7) 0.8 (0.2–2.9)
Bowel Irrigation 1,000 (NA) 7.7 (0.9–68.4) 4.3 (0.4–43.8) 5.3 (0.9–32.3)
Lavage 7.6 (0.9–61.3) 4.3 (1.1–17.1) 0 (NA) 0 (NA)
Initial antiepileptic
Phenytoin 3.7 (0.8–17.8) 2.1 (0.6–7.2) 5.1(0.8–31) 2.0 (0.4–10.3)
Phenobarbital 7.6 (0.9–61.3) 1.8 (0.5–6.2) 0 (NA) 7.3 (1.8–30.3)
Initial presentation
Acidosis 6.6 (2.5–17.5)
a 3.2 (1.4–7.0) 11.0 (1.2–97.7) 0.7 (0.2–2.8)
Hyperthermia 5.6 (1.6–20.1)
a 5.1 (1.8–14.2) 10.4 (1.8–61.4) 4.4 (1.2–16.1)
Rhabdomyolysis 8.6 (1.9–38.9)
a 2.8 (1.1–7.3) 2.4 (0.4–14.3) 1.0 (0.2–5.1)
Hyperglycemia 15.2 (3.2–73.3)
a 3.3 (1.2–9.1) 4.5 (0.4–53.2) 0 (NA)
Hypotension 12.8 (1.6–101)
a 5.3 (1.6–17.5) 7.6 (1.4–41.7) 1.5 (0.3–7.5)
Univariate analysis for primary* and secondary outcome variables, presented with odds ratios and 95% confidence intervals
aPredictors which met the criteria for inclusion into logistic regression model
20 J. Med. Toxicol. (2011) 7:16–23the patients receiving phenytoin and phenobarbital treatment
7/12 and 6/11 were intubated, respectively. Four out of five
subjects with anoxic brain injury, 7/12 subjects with status
epilepticus, and 30/49 intubated patients were hospitalized
for greater than 72 h. Of the 50 patients hospitalized for
>72 h, 19 met no other outcome measure (status epilepticus,
death, intubation, or anoxic brain inury; Fig. 1). Reasons for
prolonged hospitalization in these 19 patients included: 1
aspiration pneumonia, 3 rhabdomyolysis, 11 persistent
stupor/altered mental status, 1 cardiovascular instability,
and 3 intractable acidosis.
Factors significantly associated in the univariate analysis
with a complicated hospital course, endotracheal intubation,
status epilepticus, and anoxic brain injury/death are listed in
Table 4. Gender and age were not associated with
complicating factors. Since stimulant-induced seizures had
an association with a complicated hospital course, we
performed a descriptive subanalysis of this group. Table 5
contains the results of this analysis. In this group, 66% were
intubated, 50% were refractory to benzodiazepines, and
33% had status epilepticus.
Eight predictors met the criteria for entry into the logistic
model. Factors independently associated with a complicated
hospital course by logistic regression analysis are depicted
in Fig. 2.
Discussion
Life-threatening complications from seizures include anoxia,
respiratory failure, and status epilepticus [9, 10, 13]. Our
study attempted to identify risk factors leading to these
complications for drug-related seizures. While seizures of
any cause account for 1.2% of all ED visits, the true
incidence of drug-induced seizures is difficult to estimate
[14]. Whatever the incidence, our results suggest that there is
a relatively high complication rate (60%) in this group. This
is in contrast to the overall proportion of seizure-related
presentations to the emergency department in which nearly
75% of patients are discharged home from the emergency
department [14].
In our univariate analysis, we found seven factors to be
associated with complications. However, in the multivariate
analysis, only three predictors demonstrated statistically
significant associations: stimulant exposure, initial acidosis,
and hyperglycemia. When evaluated by substance type, we
confirmed a trend identified in previous epidemiologic
studies suggesting a declining morbidity associated with
antidepressant exposures, probably because the relatively
safer selective serotonin reuptake inhibitors have largely
supplanted the more toxic tricyclic antidepressants [4].
Conversely, we demonstrated an increasing morbidity
associated with stimulant exposures. This is congruent with
national trends published by the Drug Abuse Warning
Network [15]. Our study also found the intent of use to be
associated with complications, with unintentional exposures
having a less complicated course than suicidal overdose or
substance abuse. Although, this occurrence is likely
consistent with the experience of clinicians and toxicolo-
gists, this study confirms the significance of these trends.
In accord with our findings, a recent study demonstrated a
higher recurrence rate, higher severity, and clustering for
seizures in those patients presenting with hyperglycemia
[16]. Another recent study of patients with status epilepticus
has identified hyperglycemia to be a novel marker for poor
Table 5 Description of Stimulant exposures (N=18)
VARIABLE NUMBER
Age (mean(SD)) 27 (11.3)
Gender (male) 14
Substance
Methamphetamine 5
Cocaine 7
MDMA 3
Reason
Abuse 11
Suicide 4
Unintentional 1
Body stuffer 2
Presentation
Acidosis 4
Hyperthermia 5
Rhabdomyolysis 2
Coma 10
Hyponatremia 3
Hyperglycemia 3
Hypertensive crisis 4
Treatment
No decontamination 10
Charcoal 7
Whole bowel irrigation 3
Gastric lavage 1
Phenytoin 3
Phenobarbital 4
Propofol 3
Benzodiazepine 18
Refractory to benzodiazepines 9
Paralysis 3
Complication
Anoxic brain injury 1
Aspiration pneumonia 3
Endotracheal intubation 12
Status epilepticus 6
J. Med. Toxicol. (2011) 7:16–23 21prognosis [17]. Other studies have confirmed the association
between hyperglycemia and increased neuronal injury and
mortality in patients with seizures, stroke, and traumatic
brain injury [18–21]. Further, it has been demonstrated that
hyperglycemia enhances glutamate accumulation in the brain
[22]. Glutamate is a potent excitatory neurotransmitter,
which enhances intracellular calcium flow and cell death
but can also mediate seizure activity.
We did not expect this number of cases of hyperglycemia
and do not have comprehensive information about the
underlying presence of diabetes in our patient population.
Future studies should gather information about diabetes
prevalence and its impact on outcome. However, it seems
likely that hyperglycemia is a consequence of sympathetic
discharge and elevated circulating levels of catecholamines
which are common during seizures. It is likely that
hyperglycemia was not an indicator of diabetes prevalence
but rather a marker for seizure duration or severity.
The relationship between acidosis and neuronal injury
has similarly been established [23]. Enhanced acidosis may
exaggerate neuronal injury by facilitating free radical forma-
tion, activatingendonucleases or altering intracellular calcium
regulation [24]. This injury is further exacerbated by the
presence of acute hyperglycemia [25]. Future studies should
attempt to clarify the association between hyperglycemia,
acidosis, and seizure morbidity. Of course, it is unclear
whether acidosis and hyperglycemia were contributors to
complications or merely a manifestation of tonic–clonic
muscle activity, secondary hypoxia, and generalized stress
response. These are general incidental biomarkers, which
may reflect seizure duration and also provide leads to future
research.
An interesting finding in our study was the association
between hyperthermia and morbidity. This was especially
evident among subjects (66%) with death or anoxic brain
injury (Table 3). Although this predictor did not meet
statistical significance in the logistic regression, the
association between hyperthermia and epileptic brain
damage has been previously demonstrated [4, 26, 27].
Limitations This study has several inherent limitations.
First, health-care providers are not required to call the
poison control center, and therefore, cases are acquired
through passive surveillance. This may lead to a reporting
bias such that only less common drugs or more complicated
cases are reported. The majority of our cases, however,
were associated with common medications and drugs of
abuse. This lends some generalizability to our results.
Second, data was obtained via telephone and subject to
misinterpretation and reporting bias. Investigators were
limited to the nonuniform interpretations and assessments
of the caller and not the investigators’ direct bedside
assessment. Further, estimating the dose is imprecise in
overdose patients making the assessment of a dose-
response relationship inaccurate. Additionally, we could
not obtain reliable information about other potential
predictors such as “down time” prior to medical attention.
Since these time estimates are often only “guesses,” we
chose to eliminate this predictor from our logistic model
early in the study design.
Our sample encompassed a wide geographic region
including multiple hospital types, which may have intro-
duced treatment variations. While this enhances external
validity, certain practices (i.e., the decision to intubate) may
be based on available resources and personnel.
Our categorization of substances may not be the most
accurate way to assess complications. But we specifically
selected this classification scheme based on our previous
studies [4]. For many clinicians working in acute situations,
the classification scheme we used is a convenient and
practical way to classify substances. We did not include
coingestants into our logistic model because these were
Fig. 2 Results of logistic
regression model for complicated
hospital course
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coingestants would compromise the power of the study to
detect a difference.
Finally, due to the sample size, our study is not powered
to assess for risk factors of specific complications (i.e.,
death) other than the primary outcome. On post hoc
analysis, our sample size achieved a 79% power to detect
a difference with regards to the primary outcome measure.
We caution readers from drawing conclusions regarding the
association of certain predictors (especially treatment
factors) on secondary outcome measures, which contain
wide confidence intervals. It is possible that treatment
factors (i.e., decontamination choice, drug therapy) were
not the proximate cause of a complication but a mere
association arising from the necessity of aggressive treat-
ment measures for an acutely ill patient.
Conclusions We have observed a number of risk factors
associated with prolonged hospitalization, endotracheal
intubation, status epilepticus, anoxic brain injury, and death
for drug-induced seizures. Independent clinical factors
associated with these complications of drug-related seizures
include initial acidosis, hyperglycemia, and stimulant
exposures. Other potential risk factors include hyperthermia,
hypotension, and rhabdomyolysis. Unintentional exposures
resulting in seizures appear to have a more benign course.
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